Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of OBE 022 in healthy volunteers

Next Previous
X
Search
Trial Profile

A phase I trial of OBE 022 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ebopiprant (Primary)
  • Indications Preterm labour
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 30 Apr 2018 Results published in the British Journal of Clinical Pharmacology
    • 01 Mar 2018 Clinical safety and exposure data will be presented at the 65th Annual Meeting of the Society for Reproductive Investigation (SRI), according to an ObsEva SA media release.
    • 11 Sep 2017 According to an ObsEva media release, cardiac safety data from this trial will be presented at the 2017 Annual Meeting of the American College of Clinical Pharmacology (ACCP).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top